Wikipedia
N-Methyl-PPPA
N-Methyl-PPPA, or N-methyl-3-phenoxy-3-phenylpropan-1-amine, is a serotonin-norepinephrine reuptake inhibitor (SNRI) which was developed by Eli Lilly from diphenhydramine in the early 1970s while in search of new antidepressants, but was never marketed. It is closely related structurally to fluoxetine, atomoxetine, and nisoxetine.